Gilead Sciences (GILD) reached $141.54 at the closing of the latest trading day, reflecting a +1.97% change compared to its last close.
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript
Gilead Sciences agrees to buy German biotech company Tubulis for $3.15 billion upfront and $1.85 billion in contingency payments.
Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company's oncology pipeline.
Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, boosting the U.S. drugmaker's pipeline with a lucrative class of experimental cancer drugs referred to as "guided missiles".
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Fear is up, markets are down—and we contrarians know that times like these are when we go shopping for cheap dividends.
In the latest trading session, Gilead Sciences (GILD) closed at $139.37, marking a +2.22% move from the previous day.
Gilead Sciences, Inc. (GILD) M&A Call Transcript
Gilead Sciences (GILD) closed the most recent trading day at $134.25, moving 1.92% from the previous trading session.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.